Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis

References

• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal Cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• DevitaVTChuEA history of cancer chemotherapyCancer Res200868218643865318974103
   PubMed Web of Science ®Google Scholar
• SharmaPAllisonJPThe future of immune checkpoint therapyScience20153486230566125838373
   PubMed Web of Science ®Google Scholar
• ZouWWolchokJDChenLPD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinationsSci Transl Med20168328328rv4
   PubMed Web of Science ®Google Scholar
• KormanAJPeggsKSAllisonJPCheckpoint blockade in cancer immunotherapyAdv Immunol20069029733916730267
   PubMed Web of Science ®Google Scholar
• DongHStromeSESalomaoDRTumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasionNat Med20028879380012091876
   PubMed Web of Science ®Google Scholar
• IwaiYIshidaMTanakaYOkazakiTHonjoTMinatoNInvolvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProc Natl Acad Sci U S A20029919122931229712218188
   PubMed Web of Science ®Google Scholar
• TaubeJMKleinABrahmerJRAssociation of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapyClin Cancer Res201420195064507424714771
   PubMed Web of Science ®Google Scholar
• GaronEBRizviNAHuiRPembrolizumab for the treatment of non-small-cell lung cancerN Engl J Med2015372212018202825891174
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBMcDermottDFNivolumab versus everolimus in advanced renal-cell carcinomaN Engl J Med2015373191803181326406148
   PubMed Web of Science ®Google Scholar
• RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med2015372432033025399552
   PubMed Web of Science ®Google Scholar
• TieYMaXZhuCSafety and efficacy of nivolumab in the treatment of cancers: a meta-analysis of 27 prospective clinical trialsInt J Cancer2017140494895827813059
   PubMed Web of Science ®Google Scholar
• ChenDSIrvingBAHodiFSMolecular pathways: next-generation immunotherapy – inhibiting programmed death-ligand 1 and programmed death-1Clin Cancer Res201218246580658723087408
   PubMed Web of Science ®Google Scholar
• HerbstRSSoriaJCKowanetzMPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature2014515752856356725428504
   PubMed Web of Science ®Google Scholar
• GunturiAMcDermottDFNivolumab for the treatment of cancerExpert Opin Investig Drugs2015242253260
   PubMed Web of Science ®Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
   PubMed Web of Science ®Google Scholar
• TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumors. European Organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst200092320521610655437
   PubMed Web of Science ®Google Scholar
• HigginsJPTThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ2003327741455756012958120
   PubMed Web of Science ®Google Scholar
• BeggCBMazumdarMOperating characteristics of a RANK correlation test for publication biasBiometrics1994504108811017786990
   PubMed Web of Science ®Google Scholar
• BalarAVGalskyMDRosenbergJEAtezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialLancet201738910064677627939400
   PubMed Web of Science ®Google Scholar
• BesseBJohnsonMJannePA16LBA phase II, single-arm trial (birch) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)Eur J Cancer201551S717S718
   Web of Science ®Google Scholar
• FehrenbacherLSpiraABallingerMAtezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (poplar): a multicentre, open-label, phase 2 randomised controlled trialLancet2016387100301837184626970723
   PubMed Web of Science ®Google Scholar
• GiacconeGCamidgeDRLiuSV513 safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): a phase Ib studyEur J Cancer201551S107S108
   Web of Science ®Google Scholar
• InfanteJRBraitehFEmensLASafety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC)Ann Oncol201627Suppl 6871P
   Google Scholar
• McDermottDFSosmanJASznolMAtezolizumab, an Anti-Programmed Death-Ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia studyJ Clin Oncol201634883384226755520
   PubMed Web of Science ®Google Scholar
• PowlesTEderJPFineGDMPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature2014515752855856225428503
   PubMed Web of Science ®Google Scholar
• RittmeyerABarlesiFWaterkampDAtezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialLancet20173891006625526527979383
   PubMed Web of Science ®Google Scholar
• RosenbergJEHoffman-CensitsJPowlesTAtezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialLancet2016387100311909192026952546
   PubMed Web of Science ®Google Scholar
• SequistLVChiangAGilbertJClinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)Ann Oncol201627Suppl 61425PD
   Google Scholar
• PetersSGettingerSJohnsonMLPhase II trial of Atezolizumab as first-line or subsequent therapy for patients with programmed Death-Ligand 1-Selected advanced non-small-cell lung cancer (birch)J Clin Oncol201735242781278928609226
   PubMed Web of Science ®Google Scholar
• PetrylakDPPowlesTBellmuntJAtezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer: long-term outcomes from a phase 1 studyJAMA Oncol20184453754429423515
   PubMed Web of Science ®Google Scholar
• McDermottDFAtkinsMBMotzerRJA phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts)J Clin Oncol201735Suppl 6431
   Web of Science ®Google Scholar
• Abdel-RahmanOHelblingDSchmidtJTreatment-related death in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysisClin Oncol2017294218230
   Web of Science ®Google Scholar
• DevaudCJohnLBWestwoodJADarcyPKKershawMHImmune modulation of the tumor microenvironment for enhancing cancer immunotherapyOncoimmunology201328e2596124083084
   PubMed Web of Science ®Google Scholar
• DengRBumbacaDPastuskovasCVPreclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitorMAbs20168359360326918260
   PubMed Web of Science ®Google Scholar
• PittJMVétizouMDaillèreRResistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factorsImmunity20164461255126927332730
   PubMed Web of Science ®Google Scholar
• NishijimaTFShacharSSNyropKAMussHBSafety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysisOncologist201722447047928275115
   PubMed Web of Science ®Google Scholar
• NaidooJPageDBBtLToxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesAnn oncol201526122375239126371282
   PubMed Web of Science ®Google Scholar
• WeberJSYangJCAtkinsMBDisisMLToxicities of immunotherapy for the practitionerJ Clin Oncol201533182092209925918278
   PubMed Web of Science ®Google Scholar
• FriedmanCFProverbs-SinghTAPostowMATreatment of the immune-related adverse effects of immune checkpoint inhibitors: a reviewJAMA Oncol20162101346135327367787
   PubMed Web of Science ®Google Scholar
• CousinSSeneschalJItalianoAToxicity profiles of immunotherapyPharmacol Ther20181819110028716652
   PubMed Web of Science ®Google Scholar
• TopalianSLSznolMMcDermottDFSurvival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabJ Clin Oncol201432101020103024590637
   PubMed Web of Science ®Google Scholar
• WeberJSHodiFSWolchokJDSafety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanomaJ Clin Oncol201735778579228068177
   PubMed Web of Science ®Google Scholar
• InnoAMetroGBironzoPPathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicityTumori2017103540542128497847
   PubMed Web of Science ®Google Scholar
• ShannonVRPneumotoxicity associated with immune checkpoint inhibitor therapiesCurr Opin Pulm Med201723430531628403039
   PubMed Web of Science ®Google Scholar
• HorvatTZAdelNGDangTOImmune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering cancer centerJ Clin Oncol201533283193319826282644
   PubMed Web of Science ®Google Scholar
• GarassinoMVansteenkisteJKimJ-HPL04a.03: durvalumab in ≥3rd-line locally advanced or metastatic, EGFR/ALK wild-type NSCLC: results from the phase 2 ATLANTIC studyJ Thorac Oncol2017121S10S11
   Web of Science ®Google Scholar
• MadoreJVilainREMenziesAMPD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trialsPigment Cell Melanoma Res201528324525325477049
   PubMed Web of Science ®Google Scholar